Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring

European Journal of Endocrinology

Volumn 171, Issue 6, 2014, Pages 677-683

  Kerkhofs, T M A ^a   Derijks, L J J ^a   Ettaieb, M H T ^a   Eekhoff, E M W ^b   Neef, C ^c,d   Gelderblom, H ^e   Den Hartigh, J ^e   Guchelaar, H J ^e   Haak, H R ^a,c,d  

^a MÁXIMA MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MITOTANE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADRENAL CORTEX CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG MONITORING; FEMALE; HUMAN; MALE; MORNING DOSAGE; PATIENT CARE; PATIENT SELECTION; PROSPECTIVE STUDY; RANDOM SAMPLE; SINGLE DRUG DOSE; STANDARD; TREATMENT DURATION; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; BLOOD; CIRCADIAN RHYTHM; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; PROCEDURES;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; MALE; MITOTANE;

EID: 84911969287     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0388     Document Type: Article

References (21)

1. Temple TE Jr, Jones DJ Jr, Liddle GW & Dexter RN. Treatment of Cushing's disease. correction of hypercortisolism by o,p'DDD without induction of aldosterone deficiency. New England Journal of Medicine 1969 281 801-805. (doi:10.1056/NEJM196910092811501)
2. Fassnacht M & Allolio B. Clinical management of adrenocortical carcinoma. Best Practice & Research. Clinical Endocrinology & Metabolism 2009 23 273-289. (doi:10.1016/j.beem.2008.10.008)
3. Ghataore L, Chakraborti I, Aylwin SJ, Schulte KM, Dworakowska D, Coskeran P & Taylor NF. Effects of mitotane treatment on human steroid metabolism: implications for patient management. Endocrine Connections 2012 1 37-47. (doi:10.1530/EC-12-0028)
4. Terzolo M, Baudin E, Ardito A, Kroiss M, Leboulleux S, Daffara F, Perotti P, Feelders RA, Devries JH, Zaggia B et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. European Journal of Endocrinology 2013 169 263-270. (doi:10.1530/EJE-13-0242)
5. Terzolo M, Ardito A, Zaggia B, Laino F, Germano A, De Francia S, Daffara F & Berruti A. Management of adjuvant mitotane therapy following resection of adrenal cancer. Endocrine 2012 42 521-525. (doi:10.1007/s12020-012-9719-7)
6. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E et al. Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine 2007 356 2372-2380. (doi:10.1056/ NEJMoa063360)
7. Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M, Pentheroudakis G & on behalf of the ESMO Guidelines Working Group. Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2012 23 (suppl 7) vii131-vii138. (doi:10.1093/annonc/mds231)
8. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ & Krans HM. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. British Journal of Cancer 1994 69 947-951. (doi:10.1038/bjc.1994.183)
9. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G & Schlumberger M. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001 92 1385-1392. (doi:10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2)
10. Hermsen IG, Fassnacht M, Terz M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, SchlumbergerM et al. Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. Endocrine 2011 96 1844-1851. (doi:10.1210/jc.2010-2676)
11. Mauclere-Denost S, Leboulleux S, Borget I, Paci A, Young J, Al Ghuzlan A, Deandreis D, Drouard L, Tabarin A, Chanson P et al. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. European Journal of Endocrinology 2012 166 261-268. (doi:10.1530/EJE-11-0557)
12. Kerkhofs T, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller H, Skogseid B, Leboulleux S, Mantero F, Haak H et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2013 98 4759-4767. (doi:10.1210/jc.2013-2281)
13. Kerkhofs T, Derijks L, Ettaieb M, den Hartigh J, Neef C, Gelderblom H, Guchelaar H & Haak H. Development of a pharmacokinetic model of mitotane: towards personalized dosing in adrenocortical carcinoma. Therapeutic Drug Monitoring 2014 (In press).
14. Moolenaar AJ, van Slooten H, van Seters AP & Smeenk D. Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemotherapy and Pharmacology 1981 7 51-54. (doi:10.1007/BF00258213)
15. Hermsen IG, den Hartigh J & Haak HR. Mitotane serum level analysis; good agreement between two different assays. Clinical Endocrinology 2010 73 271-272. (doi:10.1111/j.1365-2265.2010.03787.x)
16. Moy RH. Studies of the pharmacology of o,p'DDD in man. Journal of Laboratory and Clinical Medicine 1961 58 296-304.
17. Gebhardt DO, Moolenaar AJ, van Seters AP, van der Velde EA & Gevers Leuven JA. The distribution of o,p'-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia. Cancer Chemotherapy and Pharmacology 1992 29 331-334. (doi:10.1007/ BF00685956)
18. Cai W, Benitez R, Counsell RE, Djanegara T, Schteingart DE, Sinsheimer JE & Wotring LL. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers. Biochemical Pharmacology 1995 49 1483-1489. (doi:10.1016/0006-2952(95)00028-X)
19. von Slooten H, van Seters AP, Smeenk D & Moolenaar AJ. O,p'-DDD (mitotane) levels in plasma and tissues during chemotherapy and at autopsy. Cancer Chemotherapy and Pharmacology 1982 9 85-88. (doi:10.1007/BF00265384)
20. D'Avolio A, De Francia S, Basile V, Cusato J, De Martino F, Pirro E, Piccione F, Ardito A, Zaggia B, Volante M et al. Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenetics and Genomics 2013 23 293-300. (doi:10.1097/FPC.0b013e3283606cb2)
21. Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, Volante M, Termine A, Di Carlo F, Dogliotti L et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocrine-Related Cancer 2008 15 1043-1053. (doi:10.1677/ERC-08-0103)